Optellum Secures $14 Million for Lung Cancer Innovation
Optellum, a promising medtech company based in the historic city of Oxford, UK, has recently announced a significant milestone in its journey to revolutionize lung cancer diagnosis and treatment. The firm raised an impressive $14 million in a Series A funding round, which was ably led by Mercia. This latest acquisition of funds attracted participation from several notable entities, including Intuitive Ventures, Black Opal Ventures, St John’s College at the University of Oxford, IQ Capital, and the family office of Sir Martin and Lady Audrey Wood. With this capital infusion, Optellum aims to bolster its foundational operations and facilitate commercial launches in both the UK and the USA.
The ambitious company, spearheaded by CEO Jason Pesterfield and founded by Tara Bishop, MD, has positioned itself as a frontrunner in the domain of AI-enabled lung cancer diagnosis.
It has achieved regulatory milestones by obtaining FDA clearance, CE-MDR certification in the European Union, and the UKCA mark for its innovative software platform, known as the Virtual Nodule Clinic. This cutting-edge platform equips healthcare professionals with advanced tools to identify at-risk patients and to diagnose lung cancer in its early stages. The aim is to initiate treatment at the earliest opportunity, thus improving patient outcomes while simultaneously minimizing the need for invasive procedures like biopsies on non-cancerous lesions.
Moreover, Optellum has strategically collaborated with industry giants such as GE Healthcare and the Lung Cancer Initiative at Johnson & Johnson to facilitate the swift deployment of its clinical applications and to continue refining its technological platform. In the UK, their pioneering solution is currently being utilized in a multi-center study involving NHS Trusts, marking a significant stride in the integration of artificial intelligence within the healthcare sector. To further enhance its reach, Optellum also maintains a presence in the United States, with an office located in the renowned Texas Medical Center in Houston, Texas. With these initiatives, Optellum is poised to make meaningful contributions to the fight against lung cancer, ultimately aiming for more effective, personalized treatment pathways for patients.
They've invested in Optellum
Get to know these Healthtech investors
Click here for a full list of 7,589+ startup investors in the UK